US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

152.59

+2.621.75%

Post-market: 152.590.00000.00%19:30 EDT

Volume:245.78K

Turnover:36.55M

Market Cap:2.20B

PE:-31.15

High:152.89

Open:147.95

Low:143.47

Close:149.97

52wk High:161.38

52wk Low:50.82

Shares:14.41M

Float Shares:8.40M

Volume Ratio:1.09

T/O Rate:2.93%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.8978

EPS(LYR):-3.7076

ROE:-46.63%

ROA:-22.05%

PB:10.14

PE(LYR):-41.16

Loading ...

Overview Company News Filings

Palvella Completes Rolling FDA NDA Submission for Qtorin Rapamycin in Microcystic Lymphatic Malformations

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

THOMSON REUTERS

Palvella Therapeutics - Accelerating U.S. Launch Readiness for Potential Qtorin Rapamycin Launch in H1 2027 if Approved

THOMSON REUTERS

Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Palvella Therapeutics Charts Clear Path From Data To Launch

Cumberland Pharmaceuticals Q2 Loss Widens After Apotex Transaction

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Niagen Bioscience Q2 Net Sales Fall, Missing Estimates

Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise

Palvella Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Palvella Therapeutics, Inc Q2 EPS USD -1.52

THOMSON REUTERS

Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss

MT Newswires Live

Palvella Net Loss Widens 130.88% to $21.87 Million in Q2 FY26; R&D Expenses More than Doubled to $12.47 Million

Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate

Benzinga Earnings

Press Release: Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics CSO Jeff Martini Presents at FDA Drug Repurposing Workshop

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/PVLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":152.59,"timestamp":1788206400000,"preClose":149.97,"halted":0,"volume":245779,"hourTrading":{"tag":"盘后","latestPrice":152.59,"preClose":152.59,"latestTime":"19:30 EDT","volume":10924,"amount":1667043.69272,"timestamp":1788219002402,"change":0,"changeRate":0,"amplitude":0.015818},"delay":0,"changeRate":0.01747016069880646,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"Post-Mkt","change":2.62,"latestTime":"08-31 19:32:12 EDT","open":147.95,"high":152.89,"low":143.47,"amount":36553435.07699,"amplitude":0.062813,"askPrice":240,"askSize":24,"bidPrice":144.19,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":4,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":149.97,"preHourTrading":{"tag":"盘前","latestPrice":150.49,"preClose":149.97,"latestTime":"08:48 EDT","volume":83,"amount":12486.64035,"timestamp":1788180510648,"change":0.52,"changeRate":0.003467,"amplitude":0.019737},"postHourTrading":{"tag":"盘后","latestPrice":152.59,"preClose":152.59,"latestTime":"19:30 EDT","volume":10924,"amount":1667043.69272,"timestamp":1788219002402,"change":0,"changeRate":0,"amplitude":0.015818},"volumeRatio":1.090703,"impliedVol":0.4915,"impliedVolPercentile":0.0239},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-22.05%","roe":"-46.63%","lyrEps":-3.707588,"volumeRatio":1.090703,"shares":14408407,"dividePrice":0,"high":152.89,"amplitude":0.062813,"preClose":149.97,"low":143.47,"week52Low":50.82,"pbRate":"10.14","week52High":161.38,"institutionHeld":0,"latestPrice":152.59,"committee":0.612903,"eps":-4.897784,"divideRate":0,"volume":245779,"delay":0,"ttmEps":-4.897784,"open":147.95,"prevYearClose":104.67,"prevWeekClose":149.97,"prevMonthClose":139.04,"prevQuarterClose":152.82,"fiveDayClose":145.75,"twentyDayClose":140.78,"sixtyDayClose":114.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"PVLA","fiscalQuarterEnding":"2026/06","expectedEps":-1.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-1.52},{"market":"US","date":"2026-05-07","symbol":"PVLA","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.2},{"market":"US","date":"2026-03-31","symbol":"PVLA","fiscalQuarterEnding":"2025/12","expectedEps":-0.95,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1778731200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-08-28","current":-31.154906,"percent":0.271226,"low":-60.48704,"twenty":-36.922579,"median":-28.427404,"eighty":-10.961312,"high":46.119317,"avg":-19.746107,"sd":24.379749,"marketCap":2166015824},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325},{"date":"2026-03-13","current":-55.699943,"twenty":-30.574428,"median":-17.963839,"eighty":19.083855,"marketCap":1835424534},{"date":"2026-03-20","current":-46.447881,"twenty":-31.137829,"median":-18.431476,"eighty":19.083855,"marketCap":1530550575},{"date":"2026-03-27","current":-47.956591,"twenty":-32.06614,"median":-18.561811,"eighty":19.083855,"marketCap":1580265588},{"date":"2026-04-02","current":-41.305964,"twenty":-32.945472,"median":-18.707892,"eighty":19.083855,"marketCap":1723078270},{"date":"2026-04-10","current":-44.675498,"twenty":-33.393759,"median":-19.095844,"eighty":19.083855,"marketCap":1863638401},{"date":"2026-04-17","current":-42.609857,"twenty":-34.004406,"median":-19.561706,"eighty":18.969352,"marketCap":1777470174},{"date":"2026-04-24","current":-43.594639,"twenty":-34.788907,"median":-19.977117,"eighty":18.816681,"marketCap":1818550375},{"date":"2026-05-01","current":-44.030414,"twenty":-35.208457,"median":-20.266831,"eighty":18.756249,"marketCap":1836728722},{"date":"2026-05-08","current":-32.885673,"twenty":-35.663927,"median":-20.816267,"eighty":1.605963,"marketCap":1621165018},{"date":"2026-05-15","current":-34.614036,"twenty":-35.663927,"median":-21.021819,"eighty":-9.854931,"marketCap":1706368150},{"date":"2026-05-22","current":-33.726646,"twenty":-35.536117,"median":-21.24101,"eighty":-10.054175,"marketCap":1662622476},{"date":"2026-05-29","current":-33.709189,"twenty":-35.477208,"median":-21.439742,"eighty":-10.192113,"marketCap":1661761905},{"date":"2026-06-05","current":-33.406604,"twenty":-35.361812,"median":-22.020353,"eighty":-10.267821,"marketCap":1646845348},{"date":"2026-06-12","current":-30.951006,"twenty":-35.258528,"median":-22.098288,"eighty":-10.422477,"marketCap":1525791744},{"date":"2026-06-18","current":-32.769429,"twenty":-35.21133,"median":-22.480166,"eighty":-10.551201,"marketCap":1615434519},{"date":"2026-06-26","current":-39.627064,"twenty":-35.273781,"median":-22.826974,"eighty":-10.561865,"marketCap":1953495352},{"date":"2026-07-02","current":-40.226416,"twenty":-35.557603,"median":-22.973101,"eighty":-10.565696,"marketCap":1983041611},{"date":"2026-07-10","current":-43.944726,"twenty":-36.020976,"median":-23.275097,"eighty":-10.575275,"marketCap":2166343157},{"date":"2026-07-17","current":-42.993327,"twenty":-36.290379,"median":-24.416835,"eighty":-10.577479,"marketCap":2119442057},{"date":"2026-07-24","current":-41.665152,"twenty":-36.922579,"median":-25.632611,"eighty":-10.577479,"marketCap":2053966975},{"date":"2026-07-31","current":-43.697421,"twenty":-37.223591,"median":-27.238059,"eighty":-10.749704,"marketCap":2154151740},{"date":"2026-08-07","current":-36.182159,"twenty":-37.223591,"median":-27.449273,"eighty":-10.795027,"marketCap":2232294496},{"date":"2026-08-14","current":-36.560492,"twenty":-37.14313,"median":-27.55759,"eighty":-10.795594,"marketCap":2255636115},{"date":"2026-08-21","current":-33.297956,"twenty":-36.964247,"median":-27.969419,"eighty":-10.845405,"marketCap":2054350670},{"date":"2026-08-28","current":-35.107881,"twenty":-36.922579,"median":-28.427404,"eighty":-10.961312,"marketCap":2166015824}],"updateTime":1788219132560},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663207065","title":"Palvella Completes Rolling FDA NDA Submission for Qtorin Rapamycin in Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2663207065","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663207065?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:31","pubTimestamp":1788175892,"startTime":"0","endTime":"0","summary":"Palvella completes rolling FDA NDA submission for QTORIN rapamycin in microcystic lymphatic malformationsPalvella Therapeutics completed a rolling NDA submission to the FDA for QTORIN 3.9% rapamycin g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL81tTRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014005.SGD","BK4139","IE00B64PRP62.GBP","BCDF","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","SG9999014021.USD","LU2210150020.SGD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","BK4585","PVLA","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","BK4112","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663607037","title":"Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2663607037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663607037?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:30","pubTimestamp":1788175800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUABMGH4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070325","title":"Palvella Therapeutics - Accelerating U.S. Launch Readiness for Potential Qtorin Rapamycin Launch in H1 2027 if Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663070325?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:30","pubTimestamp":1788175800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUABMGH4Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661740234","title":"Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41","url":"https://stock-news.laohu8.com/highlight/detail?id=2661740234","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661740234?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:06","pubTimestamp":1787256381,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41Palvella Therapeutics COO Kathleen Goin exercised stock options on Aug. 19, 2026, acquiring 4,302 common sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4yvj0V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521017","title":"Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521017?lang=en_us&edition=fundamental","pubTime":"2026-08-06 02:00","pubTimestamp":1785952826,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palvella Therapeutics (PVLA) and Lifecore Biomedical...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-lifecore-biomedical-lfcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-lifecore-biomedical-lfcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFCR","BK4121","PVLA","BK4212","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657654223","title":"Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657654223","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657654223?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:30","pubTimestamp":1785929400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Aug.  05, 2026  (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commerciali","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339219/0/en/Palvella-Therapeutics-to-Participate-in-the-Canaccord-Genuity-46th-Annual-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657959638","title":"Palvella Therapeutics Charts Clear Path From Data To Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2657959638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657959638?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:59","pubTimestamp":1785891560,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc. (($PVLA)) has held its Q2 earnings call. Read on for the main highlights of the call. Palvella Therapeutics’ latest ear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-charts-clear-path-from-data-to-launch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-charts-clear-path-from-data-to-launch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DECU","JOYT","BK4139","RGLO","VGFPF","GXDW","FEBU","VOTE","PVLA","PMDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657598577","title":"Cumberland Pharmaceuticals Q2 Loss Widens After Apotex Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2657598577","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657598577?lang=en_us&edition=fundamental","pubTime":"2026-08-05 06:33","pubTimestamp":1785882830,"startTime":"0","endTime":"0","summary":"Cumberland Pharmaceuticals Q2 loss widens after Apotex transactionOverviewUS biopharma firm's Q2 revenue from continuing operations fell after Apotex transaction reclassified branded business as disco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N4411HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","INDV","CPIX","LPCN","BK4007","BK4139","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657561508","title":"Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657561508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657561508?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:14","pubTimestamp":1785874443,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026OverviewUS biotech firm's Q2 net loss and pretax loss were lower than analyst expectationsQ2 results included a $40 mln ga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","LFSC","SYRE","BK4585","BK4539","DSGN","PVLA","MEDI","BK4505","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657056978","title":"Niagen Bioscience Q2 Net Sales Fall, Missing Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657056978","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657056978?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:09","pubTimestamp":1785874173,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Q2 net sales fall, missing estimatesOverviewU.S. bioscience firm's Q2 net sales declined and missed analyst expectationsQ2 net income was $1.0 mln, down from $3.6 mln a year earlierC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4121","BK4139","BK4007","BK4183","STOK","LPCN","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657569783","title":"Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569783","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569783?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:09","pubTimestamp":1785874166,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Q2 net loss widens as R&D costs riseOverviewUS biotech firm reported Q2 net loss widened to $50.2 mlnOperating expenses for Q2 rose, driven by higher R&D costs for clinical progr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4539","KROS","DNTH","PVLA","BK4139","DSGN","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656155195","title":"Palvella Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656155195","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656155195?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:31","pubTimestamp":1785850313,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryPalvella Therapeutics IncPVLA.OQreported a quarterly adjusted loss of $1.52 per share for the quarter ended Ju","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411QW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555999","title":"Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555999","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555999?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:08","pubTimestamp":1785845305,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Q2 net loss widens on higher expensesOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr amid higher R&D and admin expensesCash and short-term investments totaled $250.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N4410H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","TGTX","MEDI","BK4585","BK4007","OCUL","BK4139","PVLA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656155375","title":"Palvella Therapeutics, Inc Q2 EPS USD -1.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2656155375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656155375?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:59","pubTimestamp":1785844761,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXDC11N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656553532","title":"Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2656553532","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656553532?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:39","pubTimestamp":1785843579,"startTime":"0","endTime":"0","summary":"Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558740","title":"Palvella Net Loss Widens 130.88% to $21.87 Million in Q2 FY26; R&D Expenses More than Doubled to $12.47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558740","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558740?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:32","pubTimestamp":1785843168,"startTime":"0","endTime":"0","summary":"Palvella net loss widens 130.88% to $21.87 million in Q2 FY26; R&D expenses more than doubled to $12.47 millionPalvella posted a Q2 net loss of $21.9 million, or $1.52 a share, widening from a $9.5 mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL151NZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","PVLA","SG9999014013.SGD","IE00BKPKM429.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","BK4112","NDAQ","BCDF","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558784","title":"Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558784","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558784?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:30","pubTimestamp":1785843053,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(1.14) by 33.33 percent. This is a 76.74 percent decrease over losses of $(0.86) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60901656/palvella-therapeutics-q2-eps-1-52-misses-1-14-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656055843","title":"Press Release: Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656055843","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656055843?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:30","pubTimestamp":1785843000,"startTime":"0","endTime":"0","summary":"additional Phase 3 SELVA data during a late-breaking session at the. International Society for the Study of Vascular Anomalies World Congress. , including a statistically significant improvement in the. 6--11-year-old cohort and other supportive findings showing improvements","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","PVLA","BK4139","BK4604","03160","BK4585","TM","BK4588","LABU","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655587463","title":"Palvella Therapeutics CSO Jeff Martini Presents at FDA Drug Repurposing Workshop","url":"https://stock-news.laohu8.com/highlight/detail?id=2655587463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655587463?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:46","pubTimestamp":1785411970,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics CSO Jeff Martini presents at FDA drug repurposing workshopPalvella Therapeutics will attend an FDA public workshop on drug repurposing on Aug. 5, 2026, in Washington, D.C.Chief S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL3gN1Nf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654004329","title":"Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654004329","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654004329?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:30","pubTimestamp":1785238200,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., July  28, 2026  (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commerciali","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334141/0/en/Palvella-Therapeutics-to-Host-Second-Quarter-2026-Financial-Results-and-Corporate-Update-Conference-Call-on-August-4-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4139","BK4588","BK4181","BK4585","PVLA","HST"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":132,"code":"91000000","status":"200"}]}}